nach oben

05.03.2025 | original article

Monitoring analysis of the use of biosimilar medicines in the Campania region (southern Italy) to support effective and sustainable care

verfasst von: Francesco Ferrara, Andrea Zovi, Roberto Langella, Maurizio Capuozzo

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten

Summary

Background

Biosimilar drugs offer a valuable opportunity for healthcare systems worldwide, providing significant cost savings and ensuring the same level of effectiveness and safety in the treatment of chronic conditions. These savings can be reinvested into continuous medical innovations.

Methods

A search was carried out to assess the use of key biosimilar medications across various therapeutic areas within an Italian health authority that serves a population of over 1 million people. Data on usage, costs, and the number of patients treated were obtained from the company databases. In addition, a comparison with the year 2022 was performed, aiming to identify any increase in the use of biosimilar drugs during 2023.

Results

The analysis of 2023 revealed that a large majority of the studied active ingredients are administered as biosimilar medications, with only a few exceptions. Resistance remains in the prescription of adalimumab and etanercept, with spending on the originators of close to 3 million euros.

Conclusion

The comparison between 2023 and 2022 highlighted the growing adoption of biosimilar medications. This positive trend suggests the potential for achieving full utilization in the near future. Such a result would significantly benefit the national healthcare system and the public, ensuring a healthcare approach that is both effective and sustainable.

Valenzuela F, Flores R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics. 2021;76:e3015. https://doi.org/10.6061/clinics/2021/e3015.CrossRefPubMedPubMedCentral

Capuozzo M, Nava E, Cascone S, Cinque C, Marra R, Ottaiano A, Scognamiglio C, Palumbo E. Assessment of expenditure control and prescriptive appropriateness of biological drugs in autoimmune diseases and chronic inflammatory bowel disease. Front Pharmacol. 2013;4:31. https://doi.org/10.3389/fphar.2013.00031.CrossRefPubMedPubMedCentral

Dos Reis C, Teixo R, Mendes F, Cruz RS. Biosimilar medicines—Review. Int J Risk Saf Med. 2016;28(1):45–60. https://doi.org/10.3233/JRS-160672.CrossRefPubMed

Capuozzo M, Ottaiano A, Nava E, Cascone S, Cinque C, Iaffaioli RV, Scognamiglio C, Palumbo E, Capuozzo M. Epidemiology and economic impact of celiac disease in the South vesuvian area of naples: a survey. Front Public Health. 2013;1:18. https://doi.org/10.3389/fpubh.2013.00018.CrossRefPubMedPubMedCentral

Capozzi M, De Divitiis C, Ottaiano A, Teresa T, Capuozzo M, Maiolino P, Botti G, Tafuto S, Avallone A. Funds reimbursement of high-cost drugs in gastrointestinal oncology: an Italian real practice 1 year experience at the national cancer institute of naples. Front Public Health. 2018;6:291. https://doi.org/10.3389/fpubh.2018.00291. Abdominal Oncology Group.CrossRefPubMedPubMedCentral

Chin WW. A delicate balance—pharmaceutical innovation and access. N Engl J Med. 2015;373(19):1799–801. https://doi.org/10.1056/NEJMp1513227.CrossRefPubMed

Minghetti P, Rocco P, Del Vecchio L, Locatelli F. Biosimilars and regulatory authorities. Nephron Clin Pract. 2011;117(1):c1–c7. https://doi.org/10.1159/000319640.CrossRefPubMed

Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–7. https://doi.org/10.1182/blood-2012-04-425744.CrossRefPubMed

Curto S, Ghislandi S, van de Vooren K, Duranti S, Garattini L. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy. 2014;116(2–3):182–7. https://doi.org/10.1016/j.healthpol.2014.02.011.CrossRefPubMed

10.

Capuozzo M, Ottaiano A, Nava E, Scotti V, Cascone S, Vercellone A, Cinque C, Iaffaioli RV. Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization. Front Pharmacol. 2013;4:114. https://doi.org/10.3389/fphar.2013.00114.CrossRefPubMedPubMedCentral

11.

de Mora F. Biosimilars: a value proposition. BioDrugs. 2019;33(4):353–6. https://doi.org/10.1007/s40259-019-00360-7.CrossRefPubMed

12.

Wang YM, Strauss DG. Advancing innovations in Biosimilars. Clin Pharmacol Ther. 2023;113(1):11–5. https://doi.org/10.1002/cpt.2782.CrossRefPubMed

13.

Regione Campania. Misure di incentivazione della prescrizione di farmaci a brevetto scaduto e dei farmaci biosimilari in ambito reumatologico, gastroenterologico e dermatologico. 2023. Delibera n.583 del 13/09/2003.

14.

Italian Medicines Agency. Biosimilar medicines. 2023. https://www.aifa.gov.it/en/farmaci-biosimilari. Accessed 11.2023.

15.

Ferrara F. Antirheumatic in SARS-CoV-2: benefit or risk? Italian J Med. 2020;14(2):114–5. https://doi.org/10.4081/itjm.2020.1290.CrossRef

16.

Song YJ, Nam SW, Suh CH, Choe JY, Yoo DH. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview. Expert Opin Drug Metab Toxicol. 2023; https://doi.org/10.1080/17425255.2023.2270407.CrossRefPubMed

17.

Abitbol V, Benkhalifa S, Habauzit C, Marotte H. Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res. 2023;12(11):e230117. https://doi.org/10.57264/cer-2023-0117.CrossRefPubMedPubMedCentral

18.

Padda IS, Bhatt R, Rehman O, Parmar M. Biosimilars use in medicine for inflammatory diseases. Treasure Island: StatPearls Publishing; 2023.

19.

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-223356. Erratum in: Ann Rheum Dis. 2023 Mar;82(3):e76.CrossRefPubMed

20.

Ferrara F, Zovi A, Langella R, Cavallaro F, Nava E, Trama U, et al. New drugs for type 2 diabetes mellitus: the challenge of the health care sustainability combined with a better patient care access. Int J Healthc Manag. 2023in; https://doi.org/10.1080/20479700.2023.2210393.CrossRef

21.

Ferrara F, Vitiello A. Scientific hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 imbalance. Cardiovasc Toxicol. 2021;21(6):498–503. https://doi.org/10.1007/s12012-021-09649-y.CrossRefPubMedPubMedCentral

22.

Ferrara F, Trama U, Nava E, Capuozzo M, Zovi A, Valentino F, Langella R. Atrial fibrillation therapy with new oral anticoagulants: a real-world evidence study. Int J Healthc Manag. 2023; https://doi.org/10.1080/20479700.2023.2273025.CrossRef

23.

Capuozzo M, Celotto V, Zovi A, Langella R, Ferrara F. Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality. Eur J Health Econ. 2023; https://doi.org/10.1007/s10198-023-01640-4.CrossRefPubMed

Titel: Monitoring analysis of the use of biosimilar medicines in the Campania region (southern Italy) to support effective and sustainable care
verfasst von: Francesco Ferrara
Andrea Zovi
Roberto Langella
Maurizio Capuozzo
Publikationsdatum: 05.03.2025
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-025-01071-1